Allergan, Inc., and Inamed Corporation
The FTC required Allergan and Inamed to divest rights to Reloxin, a botulinum toxin type A product competing with Botox, as a condition of settling charges that Allergan's $3.2 billion acquisition of Inamed would substantially reduce competition in the botulinum toxin market and harm consumers through higher prices. Under the consent order, the companies were required to return Reloxin's development and distribution rights to its U.K.-based manufacturer, Ipsen Ltd. This was an antitrust enforcement action rather than a marketing-claim enforcement action.
Required actions (2)
Allergan and Inamed divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle charges that Allergan's $3.2 billion purchase of Inamed would reduce competition and force consumers to pay higher prices for botulinum toxin type A products.
the companies will return the development and distribution rights to Reloxin to Ipsen Ltd., its U.K.- based manufacturer.
Does your site contain similar claims?
The free site audit scans your whole site against every entry in this Atlas. Most medical spa / aesthetics sites match 3-6 patterns.
Run my free site auditWorried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.
Check specific copy in the Claim Checker